메뉴 건너뛰기




Volumn 83, Issue 9 B, 1999, Pages

Pathophysiology and management of low high-density lipoprotein cholesterol

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL;

EID: 0033551395     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00210-6     Document Type: Conference Paper
Times cited : (19)

References (15)
  • 2
    • 0024996141 scopus 로고
    • Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis
    • Tall A.R. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
    • (1990) J Clin Invest , vol.86 , pp. 379-384
    • Tall, A.R.1
  • 3
    • 0030017590 scopus 로고    scopus 로고
    • Unravelling high-density lipoprotein-apolipoprotein metabolism in human mutants and animal models
    • Rader D.J., Ikewaki K. Unravelling high-density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
    • (1996) Curr Opin Lipidol , vol.7 , pp. 117-123
    • Rader, D.J.1    Ikewaki, K.2
  • 4
    • 0021508760 scopus 로고
    • High-density lipoprotein metabolism
    • Eisenberg S. High-density lipoprotein metabolism. J Lipid Res. 25:1984;1017-1058.
    • (1984) J Lipid Res , vol.25 , pp. 1017-1058
    • Eisenberg, S.1
  • 5
    • 0032516013 scopus 로고    scopus 로고
    • The "best" of cholesterols, the "worst" of cholesterols. A tale of two receptors
    • Krieger M. The "best" of cholesterols, the "worst" of cholesterols. A tale of two receptors. Proc Natl Acad Sci USA. 95:1998;4077-4080.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 4077-4080
    • Krieger, M.1
  • 6
    • 0025322265 scopus 로고
    • Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit
    • Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1241.
    • (1990) J Clin Invest , vol.85 , pp. 1234-1241
    • Badimon, J.J.1    Badimon, L.2    Fuster, V.3
  • 9
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3    Heinonen, O.P.4    Heinsalmi, P.5    Helo, P.6    Huttunen, J.K.7    Kaitaniemi, P.8    Koskinen, P.9    Manninen, V.10
  • 10
    • 20244370323 scopus 로고
    • Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)
    • Goldbourt U., Behar S., Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y., Caspi A., Weisbort J., Mandelzweig L., et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 71:1993;909-915.
    • (1993) Am J Cardiol , vol.71 , pp. 909-915
    • Goldbourt, U.1    Behar, S.2    Reicher-Reiss, H.3    Agmon, J.4    Kaplinsky, E.5    Graff, E.6    Kishon, Y.7    Caspi, A.8    Weisbort, J.9    Mandelzweig, L.10
  • 11
    • 0027386876 scopus 로고
    • Rationale and Design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
    • Rubins H.B., Robins S.J., Iwane M.K., Boden W.E., Elam M.B., Fye C.L., Gordon D.J., Schaefer E.J., Schectman G., Wittes J.T. Rationale and Design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 71:1993;45-52.
    • (1993) Am J Cardiol , vol.71 , pp. 45-52
    • Rubins, H.B.1    Robins, S.J.2    Iwane, M.K.3    Boden, W.E.4    Elam, M.B.5    Fye, C.L.6    Gordon, D.J.7    Schaefer, E.J.8    Schectman, G.9    Wittes, J.T.10
  • 12
    • 0344017724 scopus 로고
    • Effects of estrogen or estrogen/progestin regimens on heart disease
    • Effects of estrogen or estrogen/progestin regimens on heart disease. Arch Intern Med. 153:1993;1528-1538.
    • (1993) Arch Intern Med , vol.153 , pp. 1528-1538
  • 14
    • 0030808288 scopus 로고    scopus 로고
    • Pharmacology of apolipoprotein A-I
    • Andersson L.O. Pharmacology of apolipoprotein A-I. Curr Opin Lipidol. 8:1997;225-228.
    • (1997) Curr Opin Lipidol , vol.8 , pp. 225-228
    • Andersson, L.O.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.